55.90
-0.04
(-0.07%)
May 17 - Close
NYSE
real-time data -
Disclaimer
Currency in USD
| Range | 55.35 - 56.23 |
| 52 week | 39.93 - 58.40 |
| Open | 55.97 |
| Vol / Avg. | 3.76M/5.70M |
| Mkt cap | 62.97B |
| P/E | 13.40 |
| Div/yield | 0.49/3.51 |
| EPS | 4.17 |
| Shares | 1.13B |
| Beta | 0.71 |
| Inst. own | 74% |
Events
Jul 24, 2013
Q2 2013 Eli Lilly Earnings Release
Jun 24, 2013
Eli Lilly Conference Call to Provide a Pipeline Update for Diabetes Business
- 8:00PM EDT -
May 6, 2013
Eli Lilly Annual Shareholder Meeting
Apr 24, 2013
Q1 2013 Eli Lilly Earnings Conference Call
Apr 24, 2013
Q1 2013 Eli Lilly Earnings Release
Mar 12, 2013
Eli Lilly at Barclays Healthcare Conference
Mar 5, 2013
Eli Lilly at Cowen Health Care Conference
Feb 26, 2013
Eli Lilly at Citi Global Healthcare Conference
|
More events from DailyFinance »
|
Key stats and ratios
| Q1 (Mar '13) | 2012 | |
| Net profit margin | 27.63% | 18.09% |
| Operating margin | 34.83% | 23.93% |
| EBITD margin | - | 31.32% |
| Return on average assets | 18.62% | 12.01% |
| Return on average equity | 41.79% | 28.89% |
| Employees | 38,100 | - |
| Carbon Disclosure Rating | - | 65/100 |
Address
LILLY CORPORATE CENTER
INDIANAPOLIS, IN 46285
United States - Map
+1-317-2762000 (Phone)
+1-317-2763492 (Fax)
INDIANAPOLIS, IN 46285
United States - Map
+1-317-2762000 (Phone)
+1-317-2763492 (Fax)
Website links
External links
Analyst Estimates - MarketWatch
SEC Filings - EDGAR Online
Major Holders - MSN Money
Research Reports - Reuters
About Company - Wikipedia
Discussion Group - Google Finance
Volume delayed by 15 mins.
Advertisement
Description
Eli Lilly and Company discovers, develops, manufactures, and sells products, in one business segment, pharmaceutical products. The Company also has an animal health business segment. It manufactures and distributes its products through facilities in the United States, Puerto Rico, and 15 other countries. Its products are sold in approximately 130 countries. The Company�s products include neuroscience products, endocrinology products, oncology products, cardiovascular products, animal health products and other pharmaceuticals. The Company�s new molecular entities (NMEs), which are in Phase III clinical trial testing include Dulaglutide, Edivoxetine, Ixekizumab, Necitumumab, New insulin glargine product, Novel basal insulin analog, Pomaglumetad Methionil, Ramucirumab, Solanezumab and Tabalumab. In February 2012, the Company acquired ChemGen Corp. On July 7, 2011, it acquired the animal health business of Janssen, a Johnson & Johnson company.
Officers and directors
| John C. Lechleiter Ph.D. | Chairman of the Board, President, Chief Executive Officer | |
| Ellen R. Marram | Acting Chairperson of the Board, Lead Independent Director | |
| Derica W. Rice | Acting Chief Executive Officer, Chief Financial Officer, Executive Vice President - Global Services | |
| Maria A. Crowe | President - Manufacturing Operations | |
| Jan M. Lundberg Ph.D. | Executive Vice President - Science and Technology, President - Lilly Research Laboratories | |
| Melissa S. Barnes | Senior Vice President - Enterprise Risk Management and Chief Ethics and Compliance Officer | |
| Michael J. Harrington | Senior Vice President, General Counsel | |
| Stephen F. Fry | Senior Vice President - Human Resources and Diversity | |
| Enrique A. Conterno | Senior Vice President and President - Lilly Diabetes | |
| Susan Mahony Ph.D. | Senior Vice President and President - Lilly Oncology |